Repligen (NASDAQ:RGEN) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Repligen (NASDAQ:RGEN) from a buy rating to a hold rating in a research note published on Saturday morning.

Several other brokerages have also recently weighed in on RGEN. Barclays reduced their price target on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. Wells Fargo & Company cut their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Finally, UBS Group dropped their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Trading Down 2.9%

Shares of Repligen stock opened at $124.97 on Friday. The stock has a market cap of $7.03 billion, a PE ratio of 147.02, a price-to-earnings-growth ratio of 2.50 and a beta of 1.15. The firm has a fifty day moving average price of $153.37 and a 200 day moving average price of $147.10. Repligen has a 1 year low of $102.96 and a 1 year high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm’s revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts predict that Repligen will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently made changes to their positions in the company. Bayforest Capital Ltd purchased a new stake in shares of Repligen during the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen during the 4th quarter worth $33,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen during the third quarter worth $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen in the fourth quarter valued at about $36,000. Finally, Hantz Financial Services Inc. raised its position in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.